Bright Minds Biosciences Inc.
DRUG
CNSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 106.44% | -465.29% | 135.31% | 65.60% | -8.67% |
| Total Depreciation and Amortization | 10.79% | 5.30% | -1.49% | 0.75% | -1.48% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -911.38% | 2.74% | -27.61% | -11.79% | -54.12% |
| Change in Net Operating Assets | -223.65% | 161.11% | 68.51% | -183.53% | 323.84% |
| Cash from Operations | -214.37% | -293.50% | 129.39% | 1.17% | 32.31% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.42% | -8.64% | 0.00% | 0.00% | -1.85% |
| Issuance of Common Stock | -- | -- | -- | -100.00% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 835,100.00% | -- | -- | -- | -- |
| Cash from Financing | 214,993.64% | -8.13% | 1.84% | -102.53% | 4,108.70% |
| Foreign Exchange rate Adjustments | 9,445.08% | -57.79% | 1,906.25% | 94.86% | 74.49% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 10,913.32% | -282.96% | 130.63% | -6,250.00% | 100.97% |